<p>华盛顿，2026 年 5 月 15 日（GLOBE NEWSWIRE）——60 Degrees Pharmaceuticals, Inc.（纳斯达克：SXTP；SXTPW）（“公司”），一家专注于开发针对传染病新药的制药公司，今天公布了截至 2026 年 3 月 31 日的 2026 财年第一季度财务业绩。</p>
<p>截至 2026 年 3 月 31 日的季度财务亮点：</p>
<ul>
<li>净产品收入从 2025 年第一季度的 164,000 美元减少约 1%，至 2026 年第一季度的约 162,000 美元。</li>
<li>公司在 2026 年第一季度实现毛利润约 76,000 美元，而 2025 年第一季度的毛利润约为 90,000 美元。</li>
<li>2026 年第一季度的运营费用约为 217 万美元，而 2025 年第一季度的运营费用约为 209 万美元。</li>
<li>2026 年第一季度归属于普通股股东的净亏损约为 221 万美元，或每股净亏损 1.28 美元，而 2025 年第一季度的净亏损约为 200 万美元，或每股净亏损 6.25 美元。</li>
</ul>
<p><strong>关于 60 Degrees Pharmaceuticals, Inc.</strong></p>
<p>60 Degrees Pharmaceuticals, Inc.成立于 2010 年，专注于开发和商业化用于治疗和预防媒介传播疾病的新药。该公司于 2018 年获得美国食品药品监督管理局对其主要产品 ARAKODA®（塔非喹）的批准。ARAKODA 在美国和澳大利亚均可商业化。60 Degrees Pharmaceuticals, Inc.还与美国和澳大利亚的知名研究和学术机构合作。60 Degrees Pharmaceuticals, Inc.总部位于华盛顿特区，在澳大利亚设有子公司。了解更多信息，请访问 www.60degreespharma.com。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本新闻稿可能包含根据 1995 年美国私人证券诉讼改革法案的安全港条款定义的 “前瞻性声明”。前瞻性声明反映了对未来事件的当前看法。当在本新闻稿中使用 “预期”、“相信”、“估计”、“期望”、“未来”、“打算”、“计划” 或这些术语的否定形式及类似表达时，均与我们或我们的管理层相关，标识前瞻性声明。前瞻性声明既不是历史事实，也不是对未来业绩的保证。相反，它们仅基于我们对未来业务、未来计划和战略、预测、预期事件和趋势、经济、监管机构活动及未来法规和其他未来条件的当前信念、期望和假设。由于前瞻性声明涉及未来，因此它们受到固有的不确定性、风险和变化的影响，这些因素难以预测，并且许多因素超出我们的控制。我们的实际业绩和财务状况可能与前瞻性声明中所指示的结果有重大差异。因此，您不应依赖这些前瞻性声明。可能导致我们的实际业绩和财务状况与前瞻性声明中所指示的结果有重大差异的重要因素包括但不限于以下几点：我们在持续经营能力方面存在重大疑虑；我们可能不符合澳大利亚政府的研究和开发税收减免资格；如果我们无法成功开发、获得 FDA 批准并及时提供塔非喹（ARAKODA®或其他方案）或澳大利亚栗提取物和/或 Celgosivir 的非疟疾预防适应症的商业化，我们可能无法扩展我们的业务运营；我们可能无法成功进行计划中的临床试验；我们没有生产能力，这使我们面临将产品推向市场的漫长且昂贵的延误风险。有关公司及可能影响前瞻性声明实现的风险因素的更详细信息，请参阅公司向证券交易委员会（“SEC”）提交的文件，包括我们于 2026 年 3 月 30 日向 SEC 提交的 10-K 表格年度报告中的信息，以及我们后续的 SEC 文件。投资者和证券持有人被敦促在 SEC 网站 www.sec.gov 上免费阅读这些文件。由于这些事项、事实变化、假设未实现或其他情况，公司的实际结果可能与本新闻稿中讨论的预期结果有重大差异。我们在本新闻稿中所做的任何前瞻性声明仅基于我们当前可获得的信息，并仅在声明之日有效。我们没有义务公开更新任何前瞻性声明，无论是书面还是口头，可能会不时做出，无论是由于新信息、未来发展还是其他原因。</p>
<p>媒体联系人：</p>
<p>Sheila A. Burke</p>
<p>SheilaBurke-consultant@60degreespharma.com</p>
<p>(484) 667-6330</p>
<p>投资者联系人：</p>
<p>Patrick Gaynes</p>
<p>patrickgaynes@60degreespharma.com</p>
<p>(310) 989-5666</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1USXpNaU0zTmpBME9URXlJekl4T0RJek16Zz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1USXpNaU0zTmpBME9URXlJekl4T0RJek16Zz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YmZhMjYyOGYtMTU4Yy00Y2M2LWE3OGItNDY4ODFlMzg2YWUxLTExOTM5MDctMjAyNi0wNS0xNS1lbg==/tiny/Sixty-Degrees-Pharmaceuticals.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YmZhMjYyOGYtMTU4Yy00Y2M2LWE3OGItNDY4ODFlMzg2YWUxLTExOTM5MDctMjAyNi0wNS0xNS1lbg==/tiny/Sixty-Degrees-Pharmaceuticals.png"/></p>

SXTP

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

医疗业 ETF - Vanguard

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

美国制药 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

<p>60 Degrees Pharmaceuticals, Inc. 发布了其 2026 年第一季度财务业绩，净产品收入略微下降至 162,000 美元，毛利润为 76,000 美元。运营费用上升至 217 万美元，导致净亏损为 221 万美元，或每股亏损 1.28 美元。该公司专注于开发传染病药物，并已获得 FDA 对其主打产品 ARAKODA®的批准</p>

<p>WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended March 31, 2026.</p>
<div class="lb-trans"><p>华盛顿，2026 年 5 月 15 日（GLOBE NEWSWIRE）——60 Degrees Pharmaceuticals, Inc.（纳斯达克：SXTP；SXTPW）（“公司”），一家专注于开发针对传染病新药的制药公司，今天公布了截至 2026 年 3 月 31 日的 2026 财年第一季度财务业绩。</p>
</div><p>Financial Highlights for the Quarter Ended March 31, 2026:</p>
<div class="lb-trans"><p>截至 2026 年 3 月 31 日的季度财务亮点：</p>
</div><ul>
<li>Net product revenues decreased approximately 1% from $164 thousand for the first quarter of 2025 to approximately $162 thousand for the first quarter of 2026.</li>
<li>The Company achieved a gross profit of approximately $76 thousand in the first quarter of 2026, compared with a gross profit of approximately $90 thousand in the first quarter of 2025.</li>
<li>Operating expenses were approximately $2.17 million in the first quarter of 2026, compared with approximately $2.09 million in the first quarter of 2025.</li>
<li>Net loss attributable to common shareholders in the first quarter of 2026 was approximately $2.21 million, or a net loss of $1.28 per share, compared with a net loss of approximately $2.00 million, or a net loss of $6.25 per share, in the first quarter of 2025.</li>
</ul>
<div class="lb-trans"><ul>
<li>净产品收入从 2025 年第一季度的 164,000 美元减少约 1%，至 2026 年第一季度的约 162,000 美元。</li>
<li>公司在 2026 年第一季度实现毛利润约 76,000 美元，而 2025 年第一季度的毛利润约为 90,000 美元。</li>
<li>2026 年第一季度的运营费用约为 217 万美元，而 2025 年第一季度的运营费用约为 209 万美元。</li>
<li>2026 年第一季度归属于普通股股东的净亏损约为 221 万美元，或每股净亏损 1.28 美元，而 2025 年第一季度的净亏损约为 200 万美元，或每股净亏损 6.25 美元。</li>
</ul>
</div><p><strong>About 60 Degrees Pharmaceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 60 Degrees Pharmaceuticals, Inc.</strong></p>
</div><p>60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine) in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.</p>
<div class="lb-trans"><p>60 Degrees Pharmaceuticals, Inc.成立于 2010 年，专注于开发和商业化用于治疗和预防媒介传播疾病的新药。该公司于 2018 年获得美国食品药品监督管理局对其主要产品 ARAKODA®（塔非喹）的批准。ARAKODA 在美国和澳大利亚均可商业化。60 Degrees Pharmaceuticals, Inc.还与美国和澳大利亚的知名研究和学术机构合作。60 Degrees Pharmaceuticals, Inc.总部位于华盛顿特区，在澳大利亚设有子公司。了解更多信息，请访问 www.60degreespharma.com。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Australian Chestnut Extract and/or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p>
<div class="lb-trans"><p>本新闻稿可能包含根据 1995 年美国私人证券诉讼改革法案的安全港条款定义的 “前瞻性声明”。前瞻性声明反映了对未来事件的当前看法。当在本新闻稿中使用 “预期”、“相信”、“估计”、“期望”、“未来”、“打算”、“计划” 或这些术语的否定形式及类似表达时，均与我们或我们的管理层相关，标识前瞻性声明。前瞻性声明既不是历史事实，也不是对未来业绩的保证。相反，它们仅基于我们对未来业务、未来计划和战略、预测、预期事件和趋势、经济、监管机构活动及未来法规和其他未来条件的当前信念、期望和假设。由于前瞻性声明涉及未来，因此它们受到固有的不确定性、风险和变化的影响，这些因素难以预测，并且许多因素超出我们的控制。我们的实际业绩和财务状况可能与前瞻性声明中所指示的结果有重大差异。因此，您不应依赖这些前瞻性声明。可能导致我们的实际业绩和财务状况与前瞻性声明中所指示的结果有重大差异的重要因素包括但不限于以下几点：我们在持续经营能力方面存在重大疑虑；我们可能不符合澳大利亚政府的研究和开发税收减免资格；如果我们无法成功开发、获得 FDA 批准并及时提供塔非喹（ARAKODA®或其他方案）或澳大利亚栗提取物和/或 Celgosivir 的非疟疾预防适应症的商业化，我们可能无法扩展我们的业务运营；我们可能无法成功进行计划中的临床试验；我们没有生产能力，这使我们面临将产品推向市场的漫长且昂贵的延误风险。有关公司及可能影响前瞻性声明实现的风险因素的更详细信息，请参阅公司向证券交易委员会（“SEC”）提交的文件，包括我们于 2026 年 3 月 30 日向 SEC 提交的 10-K 表格年度报告中的信息，以及我们后续的 SEC 文件。投资者和证券持有人被敦促在 SEC 网站 www.sec.gov 上免费阅读这些文件。由于这些事项、事实变化、假设未实现或其他情况，公司的实际结果可能与本新闻稿中讨论的预期结果有重大差异。我们在本新闻稿中所做的任何前瞻性声明仅基于我们当前可获得的信息，并仅在声明之日有效。我们没有义务公开更新任何前瞻性声明，无论是书面还是口头，可能会不时做出，无论是由于新信息、未来发展还是其他原因。</p>
</div><p>Media Contact:</p>
<div class="lb-trans"><p>媒体联系人：</p>
</div><p>Sheila A. Burke</p>
<div class="lb-trans"><p>Sheila A. Burke</p>
</div><p>SheilaBurke-consultant@60degreespharma.com</p>
<div class="lb-trans"><p>SheilaBurke-consultant@60degreespharma.com</p>
</div><p>(484) 667-6330</p>
<div class="lb-trans"><p>(484) 667-6330</p>
</div><p>Investor Contact:</p>
<div class="lb-trans"><p>投资者联系人：</p>
</div><p>Patrick Gaynes</p>
<div class="lb-trans"><p>Patrick Gaynes</p>
</div><p>patrickgaynes@60degreespharma.com</p>
<div class="lb-trans"><p>patrickgaynes@60degreespharma.com</p>
</div><p>(310) 989-5666</p>
<div class="lb-trans"><p>(310) 989-5666</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1USXpNaU0zTmpBME9URXlJekl4T0RJek16Zz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcyMTIzMiM3NjA0OTEyIzIxODIzMzg="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YmZhMjYyOGYtMTU4Yy00Y2M2LWE3OGItNDY4ODFlMzg2YWUxLTExOTM5MDctMjAyNi0wNS0xNS1lbg==/tiny/Sixty-Degrees-Pharmaceuticals.png" alt="" original-src="https://ml.globenewswire.com/media/YmZhMjYyOGYtMTU4Yy00Y2M2LWE3OGItNDY4ODFlMzg2YWUxLTExOTM5MDctMjAyNi0wNS0xNS1lbg==/tiny/Sixty-Degrees-Pharmaceuticals.png"/></p>

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results | SXTP Stock News

StockTitan

60 Degrees Pharmaceuticals

60 DEGREES PHARMACEUTICALS INC C/WTS 12/07/2028 (TO PUR COM)

60 Degrees Pharmaceuticals 公布 2026 年第一季度业绩 | SXTP 股票新闻